Stocks
ANI Pharmaceuticals Financial Statements (ANIP) |
||||||||||
| ANI Pharmaceuticalssmart-lab.ru | % | 2019 | 2020 | 2021 | 2022 | 2023 | LTM ? | |||
|---|---|---|---|---|---|---|---|---|---|---|
| Report date | 27.02.2020 | 11.03.2021 | 15.03.2022 | 09.03.2023 | 29.02.2024 | 06.08.2024 | ||||
| Currency | USD | USD | USD | USD | USD | USD | ||||
| Financial report URL | ||||||||||
| Revenue, bln rub | ? | 206.5 | 208.5 | 216.1 | 316.4 | 486.8 | 539.0 | |||
| Operating Income, bln rub | 16.4 | -16.1 | -32.5 | -25.1 | 49.5 | 47.2 | ||||
| EBITDA, bln rub | ? | 60.8 | 28.6 | 14.7 | 31.9 | 109.3 | 104.4 | |||
| Net profit, bln rub | ? | 6.09 | -22.5 | -42.6 | -47.9 | 18.8 | 27.0 | |||
| OCF, bln rub | ? | 45.6 | 15.3 | 3.32 | -31.2 | 119.0 | 112.6 | |||
| CAPEX, bln rub | ? | 27.5 | 68.3 | 23.6 | 16.5 | 18.5 | 18.4 | |||
| FCF, bln rub | ? | 18.1 | -53.1 | -20.3 | -47.7 | 100.4 | 94.2 | |||
| Dividend payout, bln rub | 0.000 | 0.000 | 0.190 | 1.63 | 1.63 | 1.63 | ||||
| Ordinary share dividend yield, % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | ||||
| Dividend payout ratio, % | 0.00% | 0.00% | 0.00% | 0.00% | 8.65% | 6.02% | ||||
| OPEX, bln rub | 127.0 | 136.9 | 143.7 | 203.3 | 196.0 | 241.3 | ||||
| Cost of production, bln rub | 63.2 | 87.2 | 100.6 | 138.8 | 241.3 | 253.0 | ||||
| R&D, bln rub | 19.8 | 16.0 | 11.4 | 22.3 | 34.3 | 38.8 | ||||
| Interest expenses, bln rub | 13.0 | 9.45 | 11.9 | 28.1 | 27.5 | 21.2 | ||||
| Assets, bln rub | 456.8 | 461.2 | 771.6 | 760.1 | 904.4 | 920.8 | ||||
| Net Assets, bln rub | ? | 212.8 | 195.7 | 358.7 | 338.5 | 432.7 | 455.8 | |||
| Debt, bln rub | 185.7 | 185.7 | 287.4 | 286.5 | 315.3 | 310.1 | ||||
| Cash, bln rub | 62.3 | 7.86 | 100.3 | 48.2 | 221.1 | 247.1 | ||||
| Net debt, bln rub | 123.4 | 177.8 | 187.1 | 238.3 | 94.2 | 63.0 | ||||
| Ordinary share price, rub | 61.7 | 29.0 | 46.1 | 40.2 | 55.1 | 62.6 | ||||
| Number of ordinary shares, mln | 11.8 | 12.0 | 12.6 | 16.3 | 18.0 | 19.3 | ||||
| Market cap, bln rub | 730 | 347 | 580 | 654 | 993 | 1 209 | ||||
| EV, bln rub | ? | 854 | 525 | 767 | 892 | 1 087 | 1 272 | |||
| Book value, bln rub | 29 | 4 | 37 | 59 | 196 | 244 | ||||
| EPS, rub | ? | 0.51 | -1.88 | -3.38 | -2.95 | 1.04 | 1.40 | |||
| FCF/share, rub | 1.53 | -4.43 | -1.61 | -2.93 | 5.58 | 4.88 | ||||
| BV/share, rub | 2.43 | 0.30 | 2.92 | 3.61 | 10.9 | 12.7 | ||||
| EBITDA margin, % | ? | 29.4% | 13.7% | 6.82% | 10.1% | 22.5% | 19.4% | |||
| Net margin, % | ? | 2.95% | -10.8% | -19.7% | -15.1% | 3.86% | 5.01% | |||
| FCF yield, % | ? | 2.48% | -15.3% | -3.50% | -7.29% | 10.1% | 7.80% | |||
| ROE, % | ? | 2.86% | -11.5% | -11.9% | -14.1% | 4.34% | 5.93% | |||
| ROA, % | ? | 1.33% | -4.89% | -5.52% | -6.30% | 2.08% | 2.93% | |||
| P/E | ? | 119.8 | -15.4 | -13.6 | -13.7 | 52.9 | 44.7 | |||
| P/FCF | 40.4 | -6.55 | -28.6 | -13.7 | 9.88 | 12.8 | ||||
| P/S | ? | 3.54 | 1.67 | 2.69 | 2.07 | 2.04 | 2.24 | |||
| P/BV | ? | 25.3 | 96.3 | 15.8 | 11.1 | 5.08 | 4.94 | |||
| EV/EBITDA | ? | 14.0 | 18.4 | 52.1 | 28.0 | 9.94 | 12.2 | |||
| Debt/EBITDA | 2.03 | 6.22 | 12.7 | 7.47 | 0.86 | 0.60 | ||||
| R&D/CAPEX, % | 71.9% | 23.4% | 48.1% | 135.6% | 185.2% | 211.3% | ||||
| CAPEX/Revenue, % | 13.3% | 32.8% | 10.9% | 5.20% | 3.80% | 3.41% | ||||
| ANI Pharmaceuticals shareholders | ||||||||||
